Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab
MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c
Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati
The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of
MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.